dMMR CRCs are notable for greater survivability, particularly in Stage II/III CRC.28, 30, 31 Retrospective studies have demonstrated improved survival in patients with MMR‐competent tumors after receiving 5‐FU‐based chemotherapy.32, 33 A large multicenter study supports the use of adjuvant chemotherapy with fluoropyrimidine plus oxaliplatin for stage III‐dMMR colon cancer.34 The extent of neutrophil infiltration in human CRC has been shown to differ based on MMR status.6, 33. This evidence concerns the gene MRC1 and colorectal carcinoma.